| Literature DB >> 15912577 |
Elisenda Rodríguez1, Anna Roig, Elies Molins, Carles Arús, María Rosa Quintero, Miquel E Cabañas, Sebastián Cerdán, Pilar Lopez-Larrubia, Coral Sanfeliu.
Abstract
The complex [(tacn)(6)Fe(8)(micro(3)-O)(2)(micro(2)-OH)(12)]Br(8).9H(2)O (Fe(8)) was evaluated in vitro as a new kind of possible MRI contrast agent. Relaxivities were measured at 1.41 and 9.4 T for Fe(8) and commercial Gd-DTPA dissolved in PBS. There was significant difference for r(1) and r(2) values between Fe(8) and Gd-DTPA at high field (9.4 T) and for r(1) at low field (1.4 T) (p<0.05). Phantom studies with T(1)-weighted MRI at 9.4 T suggest T(1) contrast potential for Fe(8). That is, up to 5.2 times higher intensity enhancement with respect to that of equimolar Gd-DTPA was obtained with an Fe(8) concentration, referred to the whole molecule, of 0.2 mM, for which no toxicity on C6 cells could be detected. No toxic effects on cultured C6 cells were observed up to a concentration of 1 mM Fe(8). Copyright (c) 2005 John Wiley & Sons, Ltd.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15912577 DOI: 10.1002/nbm.959
Source DB: PubMed Journal: NMR Biomed ISSN: 0952-3480 Impact factor: 4.044